Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Ph.D., Karl-Artur Kovar, Leopold Hermle,  Udalrich Büll, and Henning Sass. NEUROPSYCHOPHARMACOLOGY, 1999–VOL 20, NO 6, 565-581. PII S0893-133X(98)00089-X   The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4- methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg) and the drugs’ interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n 5 8). Subjects underwent two scans (control: [...]